Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• Cancer poses a significant global health challenge, with conventional treatments often proving ineffective for some patients.
• Limited therapeutic options and poor survival rates necessitate novel treatment strategies for refractory cancers.

Purpose of the Study:

• To review recent advancements in the application of single-chain fragment variable (scFv) antibodies in cancer diagnostics and therapeutics.
• To emphasize the preclinical progress and potential clinical translation of scFv-based cancer strategies.

Main Methods:

• Review of current literature on single-chain fragment variable (scFv) antibody development and application in oncology.
• Focus on preclinical studies demonstrating the efficacy and targeting capabilities of scFvs against tumor cells.

Main Results:

• Single-chain fragment variable (scFv) antibodies are effective tools for targeting tumor cells due to their antigen-binding domains.
• Preclinical research indicates significant potential for scFvs in both diagnosing and treating various cancers.

Conclusions:

• Single-chain fragment variable (scFv) antibodies represent a promising frontier in cancer immunotherapy and diagnostics.
• Further clinical trials are warranted to fully realize the therapeutic potential of scFvs in cancer patient care.